Abbott Laboratories
NYSE:ABT

126.99 USD +1.11 USD ( +0.88% )

Abbott Laboratories (NYSE:ABT)

Add ABT to Watchlist

Summary

Business Profile
Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. It has collaboration agreement with Cereno Scientific AB (publ). The company was founded in 1888 and is based in North Chicago, Illinois. [ Read More ]

Country

United States of America

Industry

Medical Devices

Market Cap

225B USD

Enterprise Value

233B USD

Dividend Yield

1%

Buyback Yield

1%

Intrinsic Valuation

ABT Intrinsic Value
Intrinsic value based on company cash flows

The intrinsic value of one ABT stock under the base scenario is 77.41 USD. Compared to the current market price of 126.99 USD, the company's shares are overvalued by 39%.

Analyst Rating

Analyst Price Target
ABT Price Target

12 month price targets for ABT stock made by Wall Street analysts. The average price target is 141.38 USD with a high forecast of 165.9 USD and a low forecast of 111.1 USD.

Lowest
Forecast
111.1 USD
Downside 13%
Average
Forecast
141.38 USD
Upside 11%
Highest
Forecast
165.9 USD
Upside 31%

Competitors

Competitors Valuation Chart
Abbott Laboratories Competitors

Competitors Valuation Table
Abbott Laboratories Competitors

Shareholder Return

Stock Performance
ABT Price Statistics

ABT Market
1 Week +1% -1%
6 Months +20% +11%
1 Year +17% +28%
3 Years +79% +70%

Stock Price
ABT Price Chart

1M
6M
1Y
3Y
5Y

Forecasted Financials

Revenue
Forecast of Future Revenue

-
-
-
-
-
-
-
-

Net Income
Forecast of Future Net Income

-
-
-
-
-
-
-
-

Abbott Laboratories Revenue and Net Income forecasts made by Wall Street analysts.